Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) and Scienture (NASDAQ:SCNX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Volatility and Risk
Enanta Pharmaceuticals has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500.
Profitability
This table compares Enanta Pharmaceuticals and Scienture’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enanta Pharmaceuticals | -106.80% | -78.58% | -23.18% |
| Scienture | N/A | -53.25% | -41.55% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enanta Pharmaceuticals | $66.98 million | 6.11 | -$81.89 million | ($3.20) | -4.41 |
| Scienture | $431,609.00 | 31.35 | -$41.51 million | ($2.76) | -0.12 |
Scienture has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for Enanta Pharmaceuticals and Scienture, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enanta Pharmaceuticals | 1 | 0 | 7 | 0 | 2.75 |
| Scienture | 1 | 0 | 1 | 0 | 2.00 |
Enanta Pharmaceuticals presently has a consensus target price of $20.29, suggesting a potential upside of 43.77%. Scienture has a consensus target price of $1.50, suggesting a potential upside of 350.45%. Given Scienture’s higher probable upside, analysts plainly believe Scienture is more favorable than Enanta Pharmaceuticals.
Institutional and Insider Ownership
95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 21.4% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Scienture beats Enanta Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
